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Aims Despite expected improvement in left ventricular (LV) systolic and diastolic function after transcatheter aortic valve
implantation (TAVI), the complex relationship between pre-existent LV systolic and diastolic function and changes in
LV haemodynamics and clinical symptoms have been scarcely investigated. This study investigated the presence of pre-
operative LV diastolic dysfunction and its improvement over time after TAVI alongside improvement in New York
Heart Association (NYHA) class in high-risk patients with severe aortic stenosis.
Methods
and results
The study population (n ¼ 358) was divided into two groups according to baseline LV ejection fraction (LVEF):
LVEF, 50% (n ¼ 96) and LVEF ≥ 50% (n ¼ 262). We compared clinical and echocardiographic parameters between
groups before TAVI, at 6 and 12months follow-up. Grade III LV diastolic dysfunction wasmore frequent in patients with
LVEF, 50% compared with patients with LVEF ≥ 50% (50.0 vs. 16.3%, P, 0.001). Systolic and diastolic echocardio-
graphic parameters improved after TAVI together with improvement in NYHA class both in patients with LVEF, 50%
(diastolic dysfunction grade ≥2: baseline 100% of patients; 12 months 58.8%, P, 0.001; NYHA III/IV: baseline, 93.8%;
12 months, 9.7%, P, 0.001) and with LVEF ≥ 50% (diastolic dysfunction grade ≥2: baseline, 87.1%; 12 months, 61.2%;
NYHA III/IV: baseline, 74.5%; 12 months, 2.6%, P, 0.001). All-cause mortality was comparable between groups.
Conclusion TAVI exerts favourable effects on LV systolic and diastolic function with a remarkable improvement in LV diastolic func-
tion associated with improvement in NYHA functional class at follow-up. Prognosis at 1 year after TAVI was not influ-
enced by baseline LV diastolic dysfunction both in patients with and without LV systolic dysfunction.
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Introduction
In the last decade, transcatheter aortic valve implantation (TAVI) has
shown to be a feasible and effective therapeutic alternative in pa-
tients with symptomatic severe aortic stenosis (AS) and contraindi-
cations or high risk for surgical aortic valve replacement.1–3 Several
studies have shown excellent, sustained transvalvular haemodynam-
ics post-TAVI, together with a significant improvement in symptoms
and quality of life.4–6 However, the impact of TAVI on left ventricu-
lar (LV) systolic and diastolic function and their association with
post-procedural improvement in quality of life and New York Heart
Association (NYHA) functional class are not well characterized.
Furthermore, despite significant LV mass regression and improve-
ment in LV systolic and diastolic function after TAVI, the complex
relationship among pre-operative LV systolic and diastolic function,
LV filling pressures, and effects of TAVI on these parameters have
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been scarcely investigated.7 – 9 These changes may have relevant
clinical prognostic value. Specifically, most patients undergoing
TAVI have symptoms related to heart failure and the patients who
presented with dyspnoea have the worst diastolic function and the
highest LV filling pressures, evidenced by largest left atrial (LA) vol-
ume and Doppler tissue imaging parameters.10 – 13 Therefore, a
comprehensive evaluation of changes of LV systolic and diastolic
function after TAVI may add significant information regarding selec-
tion criteria for the procedure, follow-up, and prognosis.
The aims of this study were to evaluate in a large consecutive ser-
ies of TAVI patients whether: (i) NYHA functional class before TAVI
correlates with pre-operative LV diastolic dysfunction parameters;
(ii) the improvement in NYHA functional class after TAVI depends
on reduction of LV filling pressures and LV diastolic changes in pa-
tients both with normal or reduced LV systolic function; (iii) severe
LV diastolic dysfunction at baseline precludesNYHA functional class
improvement after TAVI; (iv) LV diastolic function in cases with nor-
mal or depressed LV systolic function impacts on prognosis.
Methods
Study population
This study prospectively recruited 358 patients with symptomatic se-
vere AS who were referred for TAVI at Centro Cardiologico Monzino
IRCCS (Milan, Italy). All patients had a NYHA functional class ≥II. Se-
vere AS was defined as an aortic valve area (AVA) ,1 cm2 (or indexed
0.6 cm2/m2), a peak velocity .4 m/s, and a mean transaortic pressure
gradient ≥40 mmHg.14,15 All patients were considered at high operative
risk or had contraindications for conventional surgical aortic valve re-
placement. Before the procedure, a detailed clinical evaluation included
the assessment of operative risk based on the logistic EuroSCORE
and identification of associated co-morbidities and physical frailty.
Invasive angiography or multi-detector computed tomography of the
coronary/aorto-ilio-femoral arterial systems was performed in all pa-
tients. The indication for TAVI was evaluated by a multidisciplinary
team approach. The 23-mm, 26-mm, or 29-mm Edwards Sapien or
Sapien-XT transcatheter aortic valve prosthesis (Edwards Lifesciences,
Inc., Irvine, CA, USA) was used in all cases and was implanted using ei-
ther the transfemoral or transapical approach. The selection of the
prosthesis size relies on the aortic annulus evaluation by transthoracic
echocardiography (TTE), intra-operative transoesophageal echocardi-
ography, and computed tomography. Patients who had other concomi-
tant valvular disease of moderate or severe grade or atrial fibrillation or
in whom LV diastolic function evaluation was not feasible were
excluded.
The study was approved by the institutional ethics committee.
Echocardiography
Comprehensive TTE [M-mode, 2-dimensional (2D) and Doppler] was
performed using commercially available equipment (iE33, Philips Medic-
al System, Andover, MA, USA, or Vivid-7 or E9, GE Healthcare, Horten,
Norway), prior to and after the procedure and at 6 and 12 months
follow-up.
The 2D LV end-diastolic and end-systolic volumes indexed to body
surface area were obtained from the apical view. The 2D LVEF was de-
rived from the biplane Simpson method. Similarly, LA volume was mea-
sured using the biplane Simpson method.16 Maximal aortic jet velocity
was recorded from the apical, right parasternal, or suprasternal window
that yielded the highest velocity signal. Peak and mean transaortic
pressure gradients were measured using continuous-wave Doppler sig-
nal, and AVAwas estimated pre- and post-implantation by the continuity
equation, as described in the guidelines of the American Society of
Echocardiography.14,15 After the procedure, the presence of paravalvu-
lar and/or transvalvular aortic regurgitation was classified as trivial, mild,
moderate, or severe.17
LV diastolic function was assessed using both conventional and novel
diastolic parameters at each stage.18 Transmitral LV filling velocities at
the tips of the mitral valve leaflets were obtained from the apical four-
chamber view using pulse-wave Doppler echocardiography. From the
transmitral LV filling signal, the following variables were obtained:
peak early (E) and late (A) transmitral velocities, E/A ratio, and E-wave
deceleration time (DT). Tissue Doppler-derived early diastolic veloci-
ties (e′) were recorded at the medial and lateral mitral annulus, and va-
lues were expressed as mean. The dimensionless index of E/e′ was then
calculated. In addition, pulmonary artery systolic pressurewasmeasured
according to previous studies.19
Grading diastolic dysfunction
LV diastolic dysfunction was graded as mild or Grade I (impaired relax-
ation pattern), moderate or Grade II (pseudonormal pattern), and se-
vere (restrictive filling) or Grade III.18 Criteria for the grading severity
were (i) Grade I: mild diastolic dysfunction, E/A ratio ,0.8, DT .
200 ms, predominant systolic flow is seen in pulmonary venous flow,
mean annular e′ ,8 cm/sec and E/e′ ratio ,8; (ii) Grade II: moderate
diastolic dysfunction, mitral E/A ratio 0.8–1.5; E/e′ ratio 9–12, e′ , 8 cm/s,
and systolic/diastolic flow ratio is ,1; Grade II diastolic dysfunction
represents impaired myocardial relaxation with mild to moderate
elevation of LV filling pressures; (iii) Grade III, severe diastolic dysfunc-
tion, restrictive LV filling occurs, mitral E/A ratio .2, DT, 160 ms, and
average E/e′ ratio. 13 (or septal E/e′ . 15 and lateral E/e′ . 12).
Moreover, LA volume is increased in Grades II and III of diastolic dys-
function and, in the absence of pulmonary disease, increase in pulm-
onary artery pressure may be used to infer the presence of elevated
LV filling.
Statistical analysis
Continuous data are presented as mean+ SD and categorical variables
as frequencies (percentages), as appropriate. Differences between pa-
tients with LVEF, 50% and those with LVEF ≥ 50% were assessed
with unpaired Student’s t-test or Mann-Whitney U-test for continuous
variables, and with x2 test or Fischer’s exact test for categorical vari-
ables, as appropriate. One-way ANOVA for repeated measures or
Friedman test was used to analyse the repeated continuous data, and
post hoc analysis for significant results was performed using the Bonfer-
roni correction. Two-way ANOVA for repeated measures was used to
analyse differences over time between patients with LVEF, 50% and
those with LVEF ≥ 50%. Survival was evaluated using the Kaplan–Meier
analysis, and the log-rank test was used to test the differences between
groups. A P-value ,0.05 was considered statistically significant. All stat-
istical analyses were performed using SPSS 20 (SPSS Inc., Chicago, IL,
USA).
Results
A total of 358 patients underwent successful TAVI between March
2008 and February 2013. All patients received an Edwards SAPIEN
valve via the transfemoral (73%) or the transapical approach (27%).
Complete follow-up data at both 6 and 12 months were available
for 227 patients. Specifically, 15 patients did not have the echocar-
diographic examination at 6 months, 16 patients missed the
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12 months examination, and 37 patients were completely lost at
follow-up. At 12 months, 48 patients (13.4%) had died including
14 patients (3.9%) who died within the 30 days after TAVI and 34
patients (9.5%) who died during the follow-up period (Figure 1).
Baseline clinical and echocardiographic
findings
Of the total population, 96 patients (27%) had LV systolic dysfunc-
tion, defined as an LVEF, 50%, and the remaining patients (n ¼
262, 73%) had an LVEF ≥ 50% before TAVI. Table 1 provides base-
line clinical data according to LVEF. Compared with patients with
LVEF ≥ 50%, patients with LV systolic dysfunction were more likely
to be male, with lower body mass index, and more frequently had a
history of coronary artery disease, previous myocardial infarction,
percutaneous coronary intervention, atrial fibrillation, dyspnoea,
and chronic renal dysfunction. Moreover, patients with baseline
LVEF, 50% had a significantly higher logistic EuroSCORE and a
greater proportion of patients in NYHA functional class III/IV.
Baseline echocardiographic characteristics of the study popula-
tion stratified according to baseline LVEF are shown in Table 2. Pa-
tients with impaired LVEF had larger LV and LA volumes and greater
LV mass index compared with their counterparts. Mean and peak
aortic pressure gradient were lower, and AVA was smaller in pa-
tients with reduced LVEF compared with patients with LVEF ≥
50%. A higher grade of diastolic dysfunction was found in patients
with impaired baseline LVEF (LVEF, 50%: Grade II, 50.0%; Grade
III, 50.0%; LVEF ≥ 50%: Grade I, 12.9%; Grade II, 70.8%; Grade III,
16.3%; P, 0.001).
NYHA class changes and
echocardiographic outcomes
Figure 2 shows changes in the NYHA functional class and LV diastolic
dysfunction grade over time in patients with LVEF, 50% and those
with LVEF ≥ 50%. A significant improvement in the functional status
was observed at 6 and 12 months in both groups together with a
marked reduction in the degree of LV diastolic dysfunction. At
12 months follow-up, only few patients remained in LV diastolic
dysfunction Grade III and in NYHA functional class III or IV.
At 6 and 12 months after TAVI, an improvement in LVEF was ob-
served together with a significant reduction of LV end-systolic vol-
ume and LVmass index both in patients with and without LV systolic
dysfunction at baseline. Regardless of baseline LV systolic dysfunc-
tion, a trend towards a normalization of LV diastolic parameters
together with a reduction in LA volume was observed at 6 and
12 months after TAVI (Table 3). An example of a patient with a sig-
nificant improvement in LV diastolic function after TAVI is displayed
in Figure 3. The most remarkable percentage changes (normalized to
baseline value) were observed for Awave (LVEF, 50%: 35 and 37%
at 6 and 12 months; LVEF ≥ 50%: 16 and 18%), DT (LVEF, 50%: 36
and 42%; LVEF ≥ 50%: 14 and 17%), e′ (LVEF, 50%: 27 and 32%;
LVEF ≥ 50%: 21 and 23%), E/e′ ratio (LVEF, 50%: 18 and
25%; LVEF ≥ 50%: 5 and 5%), and LA volume (LVEF, 50%: 8 and
12%; LVEF ≥ 50%: 7 and 10%).
Focusing on LV diastolic parameters, on two-way ANOVA for re-
peated measures, P-values for the between-subjects effects clearly
confirm that LA volume, E wave, A wave, E/A ratio, and E/e′ ratio
were not influenced by baseline LV systolic function. Furthermore,
P-values within-subjects effects (interaction between variable and
group) show that both groups had similar changes over time for
LA volume, A wave, and e′ (Table 3).
Moreover, we did not find a correlation between paravalvular
regurgitation ≥2 and the diastolic dysfunction grade at follow-up.
Impact on survival
The causes of death during follow-up are detailed in Table 4. A simi-
lar proportion of patients with LV systolic dysfunction died at
30 days, 6, and 12 months compared with those without LV systolic
dysfunction. There were no differences in causes of death between
patients with LVEF, 50% and those with LVEF ≥ 50%.
Kaplan–Meier survival curves up to 12 months follow-up are
shown in Figure 4 according to LV systolic and diastolic dysfunction
at baseline. Mortality rates were similar in patients with LV diastolic
dysfunction ≥II and LV systolic dysfunction (no cases with systolic
dysfunction and diastolic dysfunction ,II were present in the study)
and in patients with or without diastolic dysfunction ≥II and LVEF ≥
50%.
A separate analysis of Kaplan–Meier survival curves according to
patients with or without 1-year improvement of diastolic dysfunc-
tion is shown in Figure 5. In cases with baseline diastolic dysfunction
grade ¼ 2, no differences were found according to improvement in
the diastolic dysfunction, in contrast a better survival was found in
patients with baseline diastolic dysfunction grade ¼ 3 which were
found to improve at 1 year.
Discussion
The main findings of this study are that (i) NYHA functional class is
associated with LV diastolic dysfunction at baseline in TAVI patients;
(ii) TAVI results in significant improvement of LV systolic and diastol-
ic function, reduces the LV filling pressures, and produces beneficial
effects on clinical status at the follow-up; (iii) independently on base-
line LV systolic function, severe LV diastolic dysfunction at baseline
did not preclude NYHA functional class improvement after TAVI;
Figure 1 Echocardiographic exams at follow-up. Flow chart of
the serial echocardiographic exams evaluated.
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(iv) prognosis at 1 year after TAVI is similar in patients with severe
LV diastolic dysfunction and impaired LV systolic function and in pa-
tients without severe LV systolic or diastolic dysfunction at baseline.
Cardiac haemodynamics have been extensively studied in patients
with AS.10–12 AS correction affects LV hypertrophy and LV function
to different extents. While LV hypertrophy regression and LV dia-
stolic function normalization may take years after surgical aortic
valve replacement,20 few studies suggest an early LV remodelling
after TAVI.6,8 This, in conjunction with favourable haemodynamics,
may explain the improvement of health-related quality of life after
TAVI. However, the impact of TAVI on LV systolic and diastolic func-
tion is still scarcely investigated, and the understanding of these
mechanisms is crucial for indication to TAVI, patients selection,
and prognosis.
Previous studies on TAVI haemodynamics focused more on LV
systolic function. Patients with severe LV systolic dysfunction
showed significant improvement in LVEF after TAVI.7,21,22 However,
the rate and extent of post-operative changes in LVEF are largely
variable and have not yet been entirely defined. LV function may dis-
play substantial changes in the immediate post-operative period due
to acute decrease of afterload and also intermediate and long-term
changes related to several chronic adaptations including regression
of LV hypertrophy and increase in myocardial blood flow.21,22 This
latter mechanism has been also described in the immediate
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline clinical characteristics of the overall population and comparison between patients with a baseline
EF < 50% and those with EF ≥ 50%
Variables All patients (n5 358) LVEF < 50% (n5 96) LVEF > 50% (n5 262) P
Age (years) 81+6 81+6 81+6 0.941
Male 118 (33.0%) 45 (46.9%) 73 (27.9%) 0.001
Body surface area (m2) 1.7+0.2 1.7+0.2 1.7+0.2 0.505
Body mass index (kg/m2) 25.4+4.7 24.4+3.6 25.8+5.0 0.003
Log EuroSCORE 20.5+11.6 27.5+14.2 18.0+9.3 ,0.001
NYHA functional class
I– II 73 (20.4%) 6 (6.2%) 67 (25.6%) ,0.001
III– IV 285 (79.6%) 90 (93.8%) 195 (74.4%)
Diabetes mellitus 89 (24.9%) 32 (33.3%) 57 (21.8%) 0.025
Dyslipidaemia 212 (59.6%) 56 (58.3%) 156 (60.0%) 0.776
Hypertension 313 (87.4%) 82 (85.4%) 231 (88.2%) 0.487
Current smoking 95 (27.6%) 38 (40.4%) 57 (22.8%) 0.001
Coronary artery disease 194 (54.2%) 65 (67.7%) 129 (49.2%) 0.002
Previous myocardial infarction 64 (17.9%) 34 (35.4%) 30 (11.5%) ,0.001
Previous PCI 89 (24.9%) 35 (36.5%) 54 (20.6%) 0.002
Previous CABG 51 (14.2%) 19 (19.8%) 32 (12.2%) 0.069
Peripheral vascular disease 162 (45.3%) 35 (36.5%) 127 (48.5%) 0.043
Heart rhythm
Sinus rhythm 292 (81.6%) 69 (71.9%) 223 (85.1%) 0.004
Atrial fibrillation 64 (17.9%) 27 (28.1%) 37 (14.1%) 0.002
Pacemaker 39 (10.9%) 13 (13.5%) 26 (9.9%) 0.330
Angina 120 (33.5%) 28 (29.2%) 92 (35.1%) 0.291
Dyspnoea 331 (92.5%) 94 (97.9%) 237 (90.5%) 0.018
Syncope 71 (19.8%) 14 (14.6%) 57 (21.8%) 0.132
COPD 101 (28.2%) 31 (32.3%) 70 (26.7%) 0.299
eGFR (mL/min) 49.2+21.7 42.7+19.1 51.6+22.2 0.001
eGFR, 60 mL/min 262 (73.4%) 82 (85.4%) 180 (69.0%) 0.002
Treatment
b-Blockers 159 (45.3%) 52 (55.3%) 107 (41.6%) 0.023
ACEi/ARB 215 (61.3%) 50 (53.2%) 165 (64.2%) 0.061
Diuretics 271 (77.2%) 88 (93.6%) 183 (71.2%) ,0.001
Spironolactone 83 (23.6%) 35 (37.2%) 48 (18.7%) ,0.001
Calcium antagonists 85 (24.2%) 11 (11.7%) 74 (28.8%) 0.001
Statins 136 (38.7%) 38 (40.4%) 98 (38.1%) 0.696
Anticoagulants 63 (17.9%) 28 (29.8%) 35 (13.6%) ,0.001
PCI, percutaneous coronary intervention, CABG, coronary artery bypass graft surgery; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate;
ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers.
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post-operative phases of surgical aortic valve replacement and TAVI,
as related to decrease in haemodynamic load, increase in diastolic
myocardial perfusion, in systolic component of coronary flow and
in sub-endocardial perfusion.23 All these mechanisms may also sig-
nificantly affect LV diastolic function and LV filling pressures.
In this study, we confirmed that in patients with LV systolic dys-
function, LVEF markedly improved after TAVI (from 38 to 51%)
and remained stable in patients with normal LVEF at baseline. More-
over, to determine the effects of TAVI on LV systolic and diastolic
function in the mid- and long-term follow-up of a large group of
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Baseline echocardiographic characteristics
Variables All patients (n 5 358) LVEF < 50% (n5 96) LVEF > 50% (n5 262) P
LVEDV index (mL/m2) 59+21 80+24 51+14 ,0.001
LVESV index (mL/m2) 28+17 49+18 20+8 ,0.001
LVEF (%) 56.1+12.3 39.2+6.7 62.3+7.0 ,0.001
LV mass index (g/m2) 150+41 170+41 143+38 ,0.001
Left atrial volume index (mL/m2) 57+25 65+21 55+26 ,0.001
AVA (cm2) 0.64+0.15 0.60+0.16 0.65+0.15 0.007
AVA index (cm2/m2) 0.38+0.09 0.36+0.09 0.39+0.09 0.003
Mean aortic pressure gradient (mmHg) 51+15 43+15 54+14 ,0.001
Peak aortic pressure gradient (mmHg) 83+22 71+24 88+20 ,0.001
IVST (mm) 14+2 13+2 14+2 0.006
PWT (mm) 12+2 12+2 12+2 0.090
PASP (mmHg) 42+11 46+11 40+11 ,0.001
E (cm/s) 98+33 101+36 96+32 0.200
A (cm/s) 100+32 84+36 105+30 ,0.001
E/A ratio 1.1+0.6 1.4+0.9 1.0+0.5 0.002
e′ (cm/s) 5.3+1.6 4.8+1.5 5.5+1.7 0.001
E/e′ ratio 19+7 22+8 18+6 ,0.001
Deceleration time (ms) 240+81 202+82 253+77 ,0.001
LV, left ventricular; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction; AVA, aortic valve area; IVST, interventricular septum thickness; PWT, posterior wall
thickness; PASP, pulmonary artery systolic pressure.
Figure 2 Comparison of New York Heart Association (NYHA) functional class (left) and of diastolic dysfunction grade (right) assessed at base-
line, 6, and 12 months after transchateter aortic valve implantation for patients with EF, 50% and patients with EF ≥ 50%. *P, 0.01 vs. baseline
in each group; †P, 0.01 vs. 6 months in each group.
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Table 3 Comparison of echocardiographic parameters at baseline, 6, and 12 months after TAVI for patients with EF < 50% and those with EF ≥ 50%
Variables LVEF < 50% (n5 57) LVEF > 50% (n 5 170) Two-way ANOVA
for repeated
measures
Baseline 6 months 12 months P1-v alue Baseline 6 months 12 months P1-value P2-value P3-value
LVEDV index (mL/m2) 79+24 74+23 70+21* 0.005 52+13 53+14 52+14 0.282 ,0.001 ,0.001
LVESV index (mL/m2) 49+19 38+19* 36+18* ,0.001 20+8 20+8 19+8 0.413 ,0.001 ,0.001
LVEF (%) 38.7+7.0 50.1+9.9* 51.7+11.9* ,0.001 62.6+7.2 63.3+6.9 64.4+7.4* 0.015 ,0.001 ,0.001
LV mass index (g/m2) 170+44 145+37* 143+35* ,0.001 142+35 124+33* 119+36* ,0.001 ,0.001 0.652
Left atrial volume index (mL/m2) 63+21 56+18* 54+18* ,0.001 55+29 50+25* 49+25* ,0.001 0.078 0.100
AVA (cm2) 0.61+0.15 1.82+0.36* 1.79+0.30* ,0.001 0.65+0.15 1.83+0.35* 1.82+0.36* ,0.001 0.434 0.752
AVA index (cm2/m2) 0.36+0.09 1.08+0.20* 1.08+0.20* ,0.001 0.39+0.09 1.08+0.20* 1.08+0.20* ,0.001 0.334 0.830
Mean aortic pressure gradient (mmHg) 42+15 11+4* 11+4* ,0.001 53+13 12+4* 13+5*,† ,0.001 ,0.001 ,0.001
Peak aortic pressure gradient (mmHg) 69+25 20+7* 21+7*,† ,0.001 87+20 22+7* 23+8*,† ,0.001 ,0.001 ,0.001
IVST (mm) 13+2 12+2* 12+2* ,0.001 14+2 12+2* 12+2* ,0.001 0.151 0.026
PWT (mm) 11+2 10+2* 11+2 0.004 12+2 11+2* 11+2* ,0.001 0.221 0.003
PASP (mmHg) 46+10 39+11* 37+11* ,0.001 40+10 35+8* 34+9* ,0.001 ,0.001 0.119
E (cm/s) 97+36 90+35 89+41 0.128 94+29 98+28 97+26 0.055 0.336 0.007
A (cm/s) 94+36 114+28* 114+25* ,0.001 104+30 114+30* 117+28* ,0.001 0.341 0.127
E/A ratio 1.1+0.8 0.7+0.3* 0.7+0.2* 0.004 1.0+0.5 0.9+0.4 0.8+0.3* 0.011 0.382 0.004
e′ (cm/s) 4.6+1.3 5.7+1.7* 5.9+1.4* ,0.001 5.5+1.7 6.3+1.6* 6.4+1.6* ,0.001 0.002 0.598
E/e′ ratio 21+7 15+5* 15+6* ,0.001 18+6 16+5* 16+5* ,0.001 0.408 ,0.001
Deceleration time (ms) 202+85 248+73* 263+82* ,0.001 255+77 268+64 277+65* 0.006 0.001 0.024
Paravalvular regurgitation grade 0.655 0.102 0.254 0.366
,2 46 (80.7%) 45 (78.9%) 144 (84.7%) 140 (82.4%)
≥2 11 (19.3%) 12 (21.1%) 26 (15.3%) 30 (17.6%)
LV, left ventricular; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction; AVA, aortic valve area; IVST, interventricular septum thickness; PWT, posterior wall thickness; PASP, pulmonary artery systolic pressure.
P1-value, one-way ANOVA for repeated measures; *P, 0.05, vs. baseline;
†P, 0.05, vs. 6 months.
P2-value, between-subjects effects on two-way ANOVA for repeated measures.
P3-value, within-subjects effects (interaction between variable and group) on two-way ANOVA for repeated measures.
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symptomatic severe AS patients at high surgical risk, we evaluated
several echocardiographic and Doppler parameters showing that im-
provement of symptoms in the follow-up was clearly correlated to
changes in diastolic function and reduction of LV filling pressures in-
dependently on LV systolic dysfunction at baseline. Few studies
investigated LV diastolic function after TAVI.8,9 In our study, changes
in diastolic dysfunction and LV filling pressures were assessed by
comprehensive echocardiographic and Doppler parameters. In de-
tail, the improvement of LV diastolic dysfunction and LV filling pres-
sures was associated with LV reverse remodelling (reduction in LV
Figure 3 Example of non-invasive haemodynamic improvement after TAVI. Changes after TAVI at 12 months in atrial volume (A1, A2), trans-
mitral flow Doppler (B1, B2), mitral annular tissue Doppler imaging (C1, C2), and pulmonary vein flow Doppler (D1, D2) showing improvement of
diastolic dysfunction grade.
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volumes and mass), LA reverse remodelling (reduction in LA vo-
lumes), and reduction of pulmonary artery systolic pressure. As
the severity of LV diastolic function, particularly when it leads to ele-
vated LV filling pressures, has been shown to correlate with
symptoms of dyspnoea in AS patients,10 the current study further de-
monstrated that improvement in functional status after TAVI is asso-
ciated with improvement in LV diastolic dysfunction. Accordingly,
at 12 months, few patients remained with severe LV diastolic
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Causes of death during follow-up
All patients (n5 358) LVEF < 50% (n 5 96) LVEF > 50% (n5 262) P
Intraprocedural mortality 6 (1.7%) 1 (1.0%) 5 (1.9%) 0.571
30-day mortality 14 (4.0%) 3 (3.1%) 11 (3.9%) 0.643
Death from any causes 2 (0.6%) 0 (0.0%) 2 (0.8%)
Death from cardiovascular causesa 12 (3.4%) 3 (3.1%) 9 (3.4%)
Death from stroke 0 (0.0%) 0 (0.0%) 0 (0.0%)
6-month mortality 28 (7.8%) 8 (8.3%) 20 (7.6%) 0.827
Death from any causes 19 (5.3%) 7 (7.3%) 12 (4.6%)
Death from cardiovascular causesa 26 (7.3%) 6 (6.2%) 20 (7.6%)
Death from stroke 3 (0.8%) 1 (1.0%) 2 (0.8%)
1-year mortality 48 (13.4%) 14 (14.6%) 34 (13.0%) 0.702
Death from any causes 19 (5.3%) 7 (7.3%) 12 (4.6%)
Death from cardiovascular causesa 26 (7.3%) 6 (6.2%) 20 (7.6%)
Death from stroke 3 (0.8%) 1 (1.0%) 2 (0.8%)
aDeaths from unknown causes were assumed to be deaths from cardiovascular causes.
Figure 4 Freedom from all cause of mortality at 1-year follow-up. Kaplan–Meier curves of survival according to the left ventricular ejection
fraction and to the grade of diastolic dysfunction at baseline.
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dysfunction and in NYHA functional Class III or IV. Therefore, even
the presence of severe LV diastolic dysfunction at baseline does not
preclude marked functional improvement after TAVI, and this obser-
vation is not related to the co-existence of LV systolic dysfunction.
These results may impact on selection criteria for TAVI and demon-
strates the importance of this procedure also in advanced symptom-
atic AS cases.
Park et al.11 studied a characteristic intra-cardiac haemodynamic
profile for each presenting symptoms (syncope, dyspnoea, and chest
pain) in patients with severe AS, despite a similar AVA and aortic
valve mean pressure gradient. In our patients with severe AS, larger
LA volume, lower cardiac output, lower stroke volume index, and
higher E/e′ ratio were independent determinants of the presence
of symptoms (NYHA Class III/IV). The patients who presented
with dyspnoea had the worst LV diastolic function and the highest
filling pressure, evidenced by largest LA volume, lowest e′, highest
E wave, and highest E/e′ ratio. In our study, the large majority of
cases (80%) was in NYHA functional Class III or IV and had LV dia-
stolic dysfunction, high LV filling pressures, evidenced by large LA
volume, low e′, high E wave, and high E/e′ ratio in agreement with
the study by Park and colleagues.11 Thus, the baseline clinical and
echo-Doppler characteristics of our patients represent the typical
advanced haemodynamic scenario in this pathology leading to
severe heart failure.
For many elderly patients, morbidity may be a greater concern
than mortality. A marked and durable improvement in functional
class and quality of life after TAVI has been well documented. The
randomized PARTNER trials documented a marked reduction in re-
hospitalization with transfemoral TAVI compared with medical man-
agement24 and, in comparison with surgery, a significantly shorter
length of stay as well as earlier improvement in functional status.2
Our data not only show the link between functional status and LV
systolic and diastolic function after TAVI, but also demonstrate
that the co-existence of severe LV diastolic and systolic dysfunction
has not a significant impact on 1-year mortality after TAVI. In fact,
mortality was similar in cases with LV diastolic dysfunction ≥II asso-
ciated with LV systolic dysfunction (no cases with systolic dysfunc-
tion and diastolic dysfunction ,II were present in the study) and in
cases with or without diastolic dysfunction ≥II, independently on
LVEF , or ≥50%. Therefore, TAVI may be largely beneficial in pa-
tients with advanced systolic and diastolic dysfunction and NYHA III
and IV without a prohibitive procedural risk or 1-year mortality.
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